养老院痴呆患者抗胆碱能药物与谵妄的关联:SHELTER研究结果
该横断面多中心研究纳入7个欧洲国家57家养老院的3924例患者,评估抗胆碱能药物使用与谵妄患病率的关联。痴呆组谵妄患病率为21%,非痴呆组为11%;抗胆碱能负荷(ACB和ARS)与谵妄的关联仅在痴呆组达到统计学显著性,但关联幅度 modest,尚不足以支持强推荐。
要点
- 痴呆组谵妄患病率21%,高于非痴呆组的11%。
- 抗胆碱能负荷与谵妄的关联仅在痴呆患者中达到统计学显著性。
- 痴呆患者中,ACB负荷从无/极低到强负荷,谵妄患病率仅从20%升至27%。
核心结论
- ACB量表能较好检测抗胆碱能副作用,其与养老院患者谵妄患病率正相关,但关联幅度 modest,目前不支持强推荐,需更多纵向研究。
研究设计与样本
- 横断面多中心研究,纳入7个欧洲国家57家养老院的3924例患者,属SHELTER项目。
- 采用描述性统计、百分比计算和多因素logistic分析,评估抗胆碱能药物使用与谵妄患病率的关系。
- 使用抗胆碱能风险量表(ARS)和抗胆碱能负荷量表(ACB)计算抗胆碱能负荷。
主要发现
- 根据ACB,54%的痴呆患者和60%的非痴呆患者至少使用1种抗胆碱能药物。
- 痴呆组谵妄患病率为21%,非痴呆组为11%。
- 总体上,ACB和ARS评估的抗胆碱能负荷与谵妄的比值比范围为1.07(95%CI 0.94-1.21)至1.26(95%CI 1.11-1.44),仅在痴呆组达到统计学显著性。
- 痴呆患者中,随ACB负荷增加,谵妄患病率仅轻度升高:无/极低负荷20%,中度负荷25%,强负荷27%。
关键数值与推荐
- ACB评估:痴呆患者54%、非痴呆患者60%至少使用1种抗胆碱能药物。
- 谵妄患病率:痴呆组21%,非痴呆组11%。
- 抗胆碱能负荷与谵妄的比值比范围:1.07(95%CI 0.94-1.21)至1.26(95%CI 1.11-1.44),仅在痴呆组显著。
- 痴呆患者中,ACB负荷无/极低、中度、强对应的谵妄患病率分别为20%、25%、27%。
临床怎么用
- 对养老院痴呆患者,可使用ACB量表评估抗胆碱能负荷,关注其与谵妄的潜在关联。
- 鉴于关联幅度 modest,目前不宜仅凭抗胆碱能负荷强推荐停用相关药物,需结合个体情况并开展更多纵向研究。
局限性
- 横断面设计无法确定因果关系。
- 抗胆碱能负荷与谵妄的关联幅度 modest,作者认为目前不支持强推荐。
- 需更多纵向研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Drugs with anticholinergic properties are associated with an increased prevalence of delirium, especially in older persons. The aim of this study was to evaluate the association between the use of this class of drugs in nursing home (NH) patients and prevalence of delirium, particularly in people with dementia. DESIGN: Cross-sectional multicenter study. SETTING AND PARTICIPANTS: 3924 nursing home patients of 57 nursing homes in 7 European countries participating in the Services and Health for Elderly in Long TERmcare (SHELTER) project. METHODS: Descriptive statistics, calculation of percentage, and multivariable logistic analysis were applied to describe the relationship between anticholinergic drug use and prevalence of delirium in NH patients. The Anticholinergic Risk Scale (ARS) and the Anticholinergic Burden Scale (ACB) were used to calculate the anticholinergic load. RESULTS: 54% of patients with dementia and 60% without dementia received at least 1 anticholinergic drug according to the ACB. The prevalence of delirium was higher in the dementia group (21%) compared with the nondementia group (11%). Overall, anticholinergic burden according to the ACB and ARS was associated with delirium both in patients with and without dementia, with odds ratios ranging from 1.07 [95% confidence interval (CI) 0.94-1.21] to 1.26 (95% CI 1.11-1.44). These associations reached statistical significance only in the group of patients with dementia. Among patients with dementia, delirium prevalence increased only modestly with increasing anticholinergic burden according to the ACB, from 20% (with none or minimal anticholinergic burden) to 25% (with moderate burden) and 27% delirium (with strong burden scores). CONCLUSIONS AND IMPLICATIONS: The ACB scale is relatively capable to detect anticholinergic side effects, which are positively associated with prevalence of delirium in NH patients. Given the modest nature of this association, strong recommendations are currently not warranted, and more longitudinal studies are needed.
引用
- Oudewortel L, van der Roest HG, Onder G, et al. The Association of Anticholinergic Drugs and Delirium in Nursing Home Patients With Dementia: Results From the SHELTER Study. J Am Med Dir Assoc. 2021. PMID: 34197793. doi:10.1016/j.jamda.2021.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。